Achilles tendinopathies

Salini 2015

Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Eicacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals.

OBJECTIVE

Evaluate the use of RegenPRP™ for the treatment of recalcitrant non-insertional Achilles tendinopathies and investigate whether positive outcomes depend on the age of the patients.

PROTOCOL

Retrospective study on 44 patients who had failed to respond to conservative treatment.

Patients received a total of 3 treatments at weekly intervals. RegenPRP™ (~4 ml) was injected at several sites into the degenerated tendon area. Injections were performed in sterile conditions, without anaesthesia and under ultrasound control.

Functional evaluation of Achilles tendon was performed using Victorian Institute of Sports Assessment-Achilles questionnaire (VISA-A) at baseline and at 1, 3, 6 and 12 months after the treatment. Patients were divided according to their age in two cohorts (Young <55-year-old; Elderly >55-year-old) (Fig. 1).

RESULTS

A constant and signiicant increase of the VISA-A score was observed for both patient groups during the whole length of the follow up, although better outcomes were seen in younger patients.

Improvement of Achilles tendon functionality after RegenPRP™ treatment was sustained for the 12 months of follow up.

CONCLUSION

When injected into tendon lesions, RegenPRP™ showed good outcomes in patients suffering from recalcitrant Achilles non-insertional tendinopathies.

REFERENCE

Salini V, Vanni D, Pantalone A, Abate Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Eicacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. Frontiers in aging neuroscience 2015;7:228..

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.